gilead yeztugo - Search News

News

HIV, CVS Health and Yeztugo

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV prevention breakthrough, at least for now. | CVS Health, the parent of PBM juggernaut CVS Caremark,

Zacks Investment Research on MSN · 9h

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

· 1d · on MSN

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Fierce Pharma14d

Amid excitement over Yeztugo, Gilead sees continued erosion of CAR-T sales

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while Tecartus saw a 14% drop-off to $92 million. In both cases, Gilead explained ...

14d

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

GlobalData on MSN14d

Gilead’s Yeztugo sales “ahead of expectations” following launch

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Seeking Alpha1mon

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for ...

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 Jul. 14, 2025 9:30 AM ET Gilead Sciences, Inc. (GILD) ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results